{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:21:27Z","timestamp":1793316087695,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s12026-025-09628-3","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T10:36:00Z","timestamp":1748860560000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["T-cell activation enhances anti-HER2-mediated antibody-dependent cellular cytotoxicity in gastric cancer"],"prefix":"10.1007","volume":"73","author":[{"given":"Zirui","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bosen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaodong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"issue":"10251","key":"9628_CR1","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, et al. Gastric cancer. Lancet. 2020;396(10251):635\u201348.","journal-title":"Lancet"},{"issue":"44","key":"9628_CR2","doi-asserted-by":"publisher","first-page":"e8437","DOI":"10.1097\/MD.0000000000008437","volume":"96","author":"HB Wang","year":"2017","unstructured":"Wang HB, Liao XF, Zhang J. Clinicopathological factors associated with HER2-positive gastric cancer: a meta-analysis. Medicine (Baltimore). 2017;96(44):e8437.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"9628_CR3","doi-asserted-by":"publisher","first-page":"188549","DOI":"10.1016\/j.bbcan.2021.188549","volume":"1876","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, et al. HER2-targeted therapies in gastric cancer. Biochim Biophys Acta Rev Cancer. 2021;1876(1):188549.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"3","key":"9628_CR4","first-page":"264","volume":"71","author":"SS Joshi","year":"2021","unstructured":"Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71(3):264\u201379.","journal-title":"CA Cancer J Clin"},{"issue":"42","key":"9628_CR5","doi-asserted-by":"publisher","first-page":"26787","DOI":"10.18632\/oncotarget.25507","volume":"9","author":"A Creemers","year":"2018","unstructured":"Creemers A, et al. The dynamics of HER2 status in esophageal adenocarcinoma. Oncotarget. 2018;9(42):26787\u201399.","journal-title":"Oncotarget"},{"issue":"19","key":"9628_CR6","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.3748\/wjg.v22.i19.4619","volume":"22","author":"LF Abrahao-Machado","year":"2016","unstructured":"Abrahao-Machado LF, Scapulatempo-Neto C. HER2 testing in gastric cancer: an update. World J Gastroenterol. 2016;22(19):4619\u201325.","journal-title":"World J Gastroenterol"},{"issue":"9742","key":"9628_CR7","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687\u201397.","journal-title":"Lancet"},{"issue":"4","key":"9628_CR8","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s10120-012-0219-5","volume":"16","author":"K Shiraishi","year":"2013","unstructured":"Shiraishi K, et al. Lapatinib acts on gastric cancer through both antiproliferative function and augmentation of trastuzumab-mediated antibody-dependent cellular cytotoxicity. Gastric Cancer. 2013;16(4):571\u201380.","journal-title":"Gastric Cancer"},{"issue":"24","key":"9628_CR9","doi-asserted-by":"publisher","first-page":"11991","DOI":"10.1158\/0008-5472.CAN-07-2068","volume":"67","author":"S Varchetta","year":"2007","unstructured":"Varchetta S, et al. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res. 2007;67(24):11991\u20139.","journal-title":"Cancer Res"},{"issue":"11","key":"9628_CR10","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","volume":"22","author":"MA Cooper","year":"2001","unstructured":"Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22(11):633\u201340.","journal-title":"Trends Immunol"},{"issue":"8000","key":"9628_CR11","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","volume":"626","author":"E Vivier","year":"2024","unstructured":"Vivier E, et al. Natural killer cell therapies. Nature. 2024;626(8000):727\u201336.","journal-title":"Nature"},{"issue":"1","key":"9628_CR12","first-page":"7","volume":"1","author":"D Zahavi","year":"2018","unstructured":"Zahavi D, et al. Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy. Antib Ther. 2018;1(1):7\u201312.","journal-title":"Antib Ther"},{"issue":"2","key":"9628_CR13","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/leu.2017.293","volume":"32","author":"E Casey","year":"2018","unstructured":"Casey E, et al. A new mouse expressing human Fc\u03b3 receptors to better predict therapeutic efficacy of human anti-cancer antibodies. Leukemia. 2018;32(2):547\u20139.","journal-title":"Leukemia"},{"issue":"4","key":"9628_CR14","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/74704","volume":"6","author":"RA Clynes","year":"2000","unstructured":"Clynes RA, et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6(4):443\u20136.","journal-title":"Nat Med"},{"key":"9628_CR15","doi-asserted-by":"crossref","unstructured":"Dixon KJ, Wu J, Walcheck B. Engineering anti-tumor monoclonal antibodies and Fc receptors to enhance ADCC by human NK cells. Cancers (Basel), 2021;13(2).","DOI":"10.3390\/cancers13020312"},{"issue":"3","key":"9628_CR16","doi-asserted-by":"publisher","first-page":"306","DOI":"10.21147\/j.issn.1000-9604.2024.03.07","volume":"36","author":"Z Li","year":"2024","unstructured":"Li Z, et al. Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer. Chin J Cancer Res. 2024;36(3):306\u201321.","journal-title":"Chin J Cancer Res"},{"issue":"7","key":"9628_CR17","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1158\/1078-0432.CCR-18-2275","volume":"25","author":"F Meric-Bernstam","year":"2019","unstructured":"Meric-Bernstam F, et al. Advances in HER2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer. Clin Cancer Res. 2019;25(7):2033\u201341.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"9628_CR18","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1002\/mc.22241","volume":"54","author":"C Yun","year":"2015","unstructured":"Yun C, et al. Essential role of Her3 in two signaling transduction patterns: Her2\/Her3 and MET\/Her3 in proliferation of human gastric cancer. Mol Carcinog. 2015;54(12):1700\u20139.","journal-title":"Mol Carcinog"},{"issue":"1","key":"9628_CR19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","volume":"17","author":"DY Oh","year":"2020","unstructured":"Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17(1):33\u201348.","journal-title":"Nat Rev Clin Oncol"},{"issue":"18","key":"9628_CR20","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1182\/blood.2023023370","volume":"143","author":"J Arora","year":"2024","unstructured":"Arora J, et al. T cell help in the tumor microenvironment enhances rituximab-mediated NK cell ADCC. Blood. 2024;143(18):1816\u201324.","journal-title":"Blood."},{"issue":"2","key":"9628_CR21","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00262-021-02976-7","volume":"71","author":"Z Wang","year":"2022","unstructured":"Wang Z, et al. T cells, particularly activated CD4(+) cells, maintain anti-CD20-mediated NK cell viability and antibody dependent cellular cytotoxicity. Cancer Immunol Immunother. 2022;71(2):237\u201349.","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"9628_CR22","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.immuni.2018.01.007","volume":"48","author":"BV Kumar","year":"2018","unstructured":"Kumar BV, Connors TJ, Farber DL. Human T cell development, localization, and function throughout life. Immunity. 2018;48(2):202\u201313.","journal-title":"Immunity"},{"issue":"3","key":"9628_CR23","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.immuni.2007.02.009","volume":"26","author":"A Laurence","year":"2007","unstructured":"Laurence A, et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity. 2007;26(3):371\u201381.","journal-title":"Immunity"},{"issue":"3","key":"9628_CR24","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/0022-1759(74)90109-4","volume":"5","author":"D English","year":"1974","unstructured":"English D, Andersen BR. Single-step separation of red blood cells, granulocytes and mononuclear leukocytes on discontinuous density gradients of Ficoll-Hypaque. J Immunol Methods. 1974;5(3):249\u201352.","journal-title":"J Immunol Methods"},{"issue":"10","key":"9628_CR25","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1517\/13543784.17.10.1553","volume":"17","author":"P Kiewe","year":"2008","unstructured":"Kiewe P, Thiel E. Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opin Investig Drugs. 2008;17(10):1553\u20138.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"9628_CR26","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1016\/S1470-2045(13)70334-6","volume":"15","author":"MD Hellmann","year":"2014","unstructured":"Hellmann MD, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014;15(1):e42-50.","journal-title":"Lancet Oncol"},{"issue":"10","key":"9628_CR27","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s41577-018-0046-y","volume":"18","author":"R Spolski","year":"2018","unstructured":"Spolski R, Li P, Leonard WJ. Biology and regulation of IL-2: from molecular mechanisms to human therapy. Nat Rev Immunol. 2018;18(10):648\u201359.","journal-title":"Nat Rev Immunol"},{"issue":"670","key":"9628_CR28","doi-asserted-by":"publisher","first-page":"eabo5409","DOI":"10.1126\/scitranslmed.abo5409","volume":"14","author":"ME Raeber","year":"2022","unstructured":"Raeber ME, Sahin D, Boyman O. Interleukin-2-based therapies in cancer. Sci Transl Med. 2022;14(670):eabo5409.","journal-title":"Sci Transl Med"},{"issue":"1","key":"9628_CR29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jcmgh.2021.09.005","volume":"13","author":"MJ Pang","year":"2022","unstructured":"Pang MJ, et al. Gastric organoids: progress and remaining challenges. Cell Mol Gastroenterol Hepatol. 2022;13(1):19\u201333.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"6625","key":"9628_CR30","doi-asserted-by":"publisher","first-page":"eaba1624","DOI":"10.1126\/science.aba1624","volume":"378","author":"GM Allen","year":"2022","unstructured":"Allen GM, et al. Synthetic cytokine circuits that drive T cells into immune-excluded tumors. Science. 2022;378(6625):eaba1624.","journal-title":"Science"},{"issue":"4","key":"9628_CR31","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1002\/jcp.29216","volume":"235","author":"A Derakhshani","year":"2020","unstructured":"Derakhshani A, et al. Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy. J Cell Physiol. 2020;235(4):3142\u201356.","journal-title":"J Cell Physiol"},{"issue":"2","key":"9628_CR32","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s12016-019-08741-0","volume":"58","author":"A Bordron","year":"2020","unstructured":"Bordron A, et al. Complement system: a neglected pathway in immunotherapy. Clin Rev Allergy Immunol. 2020;58(2):155\u201371.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"3","key":"9628_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/antib9030034","volume":"9","author":"D Zahavi","year":"2020","unstructured":"Zahavi D, Weiner L. Monoclonal antibodies in cancer therapy. Antibodies. 2020;9(3):34.","journal-title":"Antibodies"},{"issue":"18","key":"9628_CR34","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.1158\/0008-5472.CAN-21-1109","volume":"81","author":"LC Tsao","year":"2021","unstructured":"Tsao LC, Force J, Hartman ZC. Mechanisms of therapeutic antitumor monoclonal antibodies. Cancer Res. 2021;81(18):4641\u201351.","journal-title":"Cancer Res"},{"issue":"1","key":"9628_CR35","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41392-021-00629-w","volume":"6","author":"G Zheng","year":"2021","unstructured":"Zheng G, et al. Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab. Signal Transduct Target Ther. 2021;6(1):236.","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"9628_CR36","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.cell.2020.02.019","volume":"180","author":"HY Chew","year":"2020","unstructured":"Chew HY, et al. Endocytosis inhibition in humans to improve responses to ADCC-mediating antibodies. Cell. 2020;180(5):895-914.e27.","journal-title":"Cell"},{"issue":"12","key":"9628_CR37","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1002\/(SICI)1097-0142(19970615)79:12<2320::AID-CNCR5>3.0.CO;2-P","volume":"79","author":"S Coca","year":"1997","unstructured":"Coca S, et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer. 1997;79(12):2320\u20138.","journal-title":"Cancer"},{"key":"9628_CR38","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.3389\/fimmu.2020.01242","volume":"11","author":"S Zhang","year":"2020","unstructured":"Zhang S, et al. Prognostic significance of tumor-infiltrating natural killer cells in solid tumors: a systematic review and meta-analysis. Front Immunol. 2020;11:1242.","journal-title":"Front Immunol"},{"key":"9628_CR39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1600-065X.2006.00457.x","volume":"214","author":"YT Bryceson","year":"2006","unstructured":"Bryceson YT, et al. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev. 2006;214:73\u201391.","journal-title":"Immunol Rev"},{"issue":"1\u20132","key":"9628_CR40","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jim.2005.06.018","volume":"304","author":"JA Bowles","year":"2005","unstructured":"Bowles JA, Weiner GJ. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods. 2005;304(1\u20132):88\u201399.","journal-title":"J Immunol Methods"},{"issue":"7","key":"9628_CR41","doi-asserted-by":"publisher","first-page":"509","DOI":"10.4251\/wjgo.v11.i7.509","volume":"11","author":"M Lin","year":"2019","unstructured":"Lin M, et al. Utilizing gastric cancer organoids to assess tumor biology and personalize medicine. World J Gastrointest Oncol. 2019;11(7):509\u201317.","journal-title":"World J Gastrointest Oncol"},{"issue":"4","key":"9628_CR42","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41575-019-0255-2","volume":"17","author":"HCH Lau","year":"2020","unstructured":"Lau HCH, et al. Organoid models of gastrointestinal cancers in basic and translational research. Nat Rev Gastroenterol Hepatol. 2020;17(4):203\u201322.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6444","key":"9628_CR43","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1126\/science.aaw6985","volume":"364","author":"D Tuveson","year":"2019","unstructured":"Tuveson D, Clevers H. Cancer modeling meets human organoid technology. Science. 2019;364(6444):952\u20135.","journal-title":"Science"},{"issue":"1","key":"9628_CR44","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12967-020-02677-2","volume":"19","author":"L Liu","year":"2021","unstructured":"Liu L, et al. Patient-derived organoid (PDO) platforms to facilitate clinical decision making. J Transl Med. 2021;19(1):40.","journal-title":"J Transl Med"},{"key":"9628_CR45","doi-asserted-by":"publisher","first-page":"118300","DOI":"10.1016\/j.lfs.2020.118300","volume":"260","author":"F Guo","year":"2020","unstructured":"Guo F, Cui J. CAR-T in solid tumors: blazing a new trail through the brambles. Life Sci. 2020;260:118300.","journal-title":"Life Sci"},{"issue":"1","key":"9628_CR46","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-023-01735-9","volume":"22","author":"Q Liu","year":"2023","unstructured":"Liu Q, et al. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T. Mol Cancer. 2023;22(1):28.","journal-title":"Mol Cancer"},{"issue":"1","key":"9628_CR47","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel CL, et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol. 2023;20(1):49\u201362.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"9628_CR48","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47\u201362.","journal-title":"Nat Rev Clin Oncol"},{"key":"9628_CR49","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.pharmthera.2016.06.010","volume":"166","author":"GL Beatty","year":"2016","unstructured":"Beatty GL, O\u2019Hara M. Chimeric antigen receptor-modified T cells for the treatment of solid tumors: defining the challenges and next steps. Pharmacol Ther. 2016;166:30\u20139.","journal-title":"Pharmacol Ther"},{"issue":"12","key":"9628_CR50","first-page":"3718","volume":"8","author":"GF Fleming","year":"2002","unstructured":"Fleming GF, et al. A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res. 2002;8(12):3718\u201327.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"9628_CR51","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10549-008-0251-7","volume":"117","author":"A Mani","year":"2009","unstructured":"Mani A, et al. A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. Breast Cancer Res Treat. 2009;117(1):83\u20139.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"9628_CR52","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.4049\/jimmunol.130.5.2203","volume":"130","author":"JH Donohue","year":"1983","unstructured":"Donohue JH, Rosenberg SA. The fate of interleukin-2 after in vivo administration. J Immunol. 1983;130(5):2203\u20138.","journal-title":"J Immunol"},{"key":"9628_CR53","doi-asserted-by":"crossref","unstructured":"Chaudhary B, Elkord E. Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting. Vaccines (Basel). 2016;6:4(3):28.","DOI":"10.3390\/vaccines4030028"},{"issue":"2","key":"9628_CR54","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/sj.bmt.1704086","volume":"32","author":"LJ Burns","year":"2003","unstructured":"Burns LJ, et al. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I\/II trial. Bone Marrow Transplant. 2003;32(2):177\u201386.","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"9628_CR55","doi-asserted-by":"publisher","first-page":"3958","DOI":"10.1158\/0008-5472.CAN-12-0146","volume":"72","author":"N Eissler","year":"2012","unstructured":"Eissler N, et al. Trifunctional bispecific antibodies induce tumor-specific T cells and elicit a vaccination effect. Cancer Res. 2012;72(16):3958\u201366.","journal-title":"Cancer Res"},{"issue":"7900","key":"9628_CR56","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/s41586-022-04439-0","volume":"603","author":"E Seung","year":"2022","unstructured":"Seung E, et al. A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells. Nature. 2022;603(7900):328\u201334.","journal-title":"Nature"},{"issue":"3","key":"9628_CR57","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41571-022-00721-2","volume":"20","author":"J Chuprin","year":"2023","unstructured":"Chuprin J, et al. Humanized mouse models for immuno-oncology research. Nat Rev Clin Oncol. 2023;20(3):192\u2013206.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"9628_CR58","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.4049\/jimmunol.172.5.2731","volume":"172","author":"J Mestas","year":"2004","unstructured":"Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol. 2004;172(5):2731\u20138.","journal-title":"J Immunol"},{"issue":"1","key":"9628_CR59","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12916-022-02421-1","volume":"20","author":"K Jia","year":"2022","unstructured":"Jia K, et al. Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer. BMC Med. 2022;20(1):223.","journal-title":"BMC Med"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-025-09628-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-025-09628-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-025-09628-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T08:03:26Z","timestamp":1770192206000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-025-09628-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["9628"],"URL":"https:\/\/doi.org\/10.1007\/s12026-025-09628-3","relation":{},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]},"assertion":[{"value":"16 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Ethical approval for this study (B2024 -\u2009104) was provided by the Ethical Committee of Zhongshan Hospital, Fudan University, on 11 March 2024.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Participants consent to publish their data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict\u00a0of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"88"}}